Cohance Lifesciences, a finished-drug maker, was cited for inadequate investigations and dirty shared equipment that caused cross-contamination.
What happened
FDA inspected the facility from August 4 to August 12, 2025. It found inadequate investigations of customer complaints about crumbling, disintegrating, pitted tablets and visible stains/residues on equipment documented as clean, with multiple active ingredients above the company's allowable limit.
What FDA found
The company did not thoroughly investigate complaints and quality failures, including tablets reported as crumbling, disintegrating, pitted, and dusty, and did not establish root cause or effective corrective actions.
21 CFR 211.192The company did not adequately clean and maintain shared manufacturing equipment; visible stains and residues on equipment documented as clean contained multiple active drug ingredients above the allowed limit.
21 CFR 211.67(a)The company lacked adequate written cleaning and maintenance procedures and its cleaning validation did not use the worst-case drug product or verify routine cleaning effectiveness.
21 CFR 211.67(b)
What FDA wants
FDA asks the company to respond in writing within 15 working days with corrective actions and prevention plans, including independent assessments of investigations, CAPA, and cleaning. FDA also asks it to clarify when it will resume U.S. drug manufacturing and to notify FDA before resuming.
Who should pay attention
- brands that rely on this contract manufacturer for U.S. finished drugs
- patients taking drugs made at this facility
- companies that share equipment across multiple drug products
This is a summary. Read the original letter on fda.gov.